According to the LOOKING AHEAD statement in the company presentation the following is what we can expect -
Initiate stable cell line development for PAT-DX1 - Q1, 2018
Select target indication for PAT-DX1 clinical development - Q2, 2018
Partnership discussions Deoxymab and lgM platforms - Ongoing
Collaborations - Ongoing
They have delivered on the other four items in the statement so I am hopeful that we will se some progress on the rest of the programs.
PAB chart, page-469
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.8¢ | $8 | 1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 8034700 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1995944 | 7 |
View Market Depth
| Last trade - 10.06am 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.7¢ |
Change
0.000 ( 12.5 %) |
||||
| Open | High | Low | Volume | ||
| 0.7¢ | 0.7¢ | 0.7¢ | 30000 | ||
| Last updated 11.14am 27/05/2024 ? | |||||
| PAB (ASX) Chart |